Pollack, Karlyn E
Meneveau, Max O https://orcid.org/0000-0002-8410-061X
Melssen, Marit M
Lynch, Kevin T
Koeppel, Alexander F
Young, Samuel J
Turner, Stephen
Kumar, Pankaj
Sol-Church, Katia
Mauldin, Ileana S
Slingluff Jr, Craig L
Clinical trials referenced in this document:
Documents that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
Documents that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
340 Cancer vaccination induces high-avidity T cell receptors reactive to endogenously presented target antigens for use in future T cell therapies for HLA-A*03:01
<sup>+</sup>
cancer patients
https://doi.org/10.1136/jitc-2025-sitc2025.0340
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
Documents that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
Funding for this research was provided by:
Cancer Research Institute (CLIP Award)
National Institutes of Health (5T32CA163177-08)